A global network promoting objective and open debate on drug policy
Australian Drug Foundation have organized a free webinar in Melbourne about new and emerging drugs, that represent one of the biggest challenges in the alcohol and other drug field for 2013 in Australia.
The aim of this second TEDI' s report is to present the results of the data that has been gathered, analysed and compared by six harm reduction groups during the seven-month period June–December 2012 in five countries.
Methamphetamine remains "the top illicit drug threat" in East and South-East Asia, according to a new UNODC report, the 2012 Patterns and Trends of Amphetamine-Type Stimulants and Other Drugs, Asia and the Pacific.
This network of European fieldwork drug checking services shares expertise and data within a European monitoring and information system. This trend report includes 1,690 analyses from the period January to May 2012.
During a special thematic debate on drugs and crime as a threat to development, Mr. Fedotov said that with the 2015 deadline approaching to take stock of global progress towards achieving the Millennium Development Goals, there is an increasing recognition that organized crime and illicit drugs...
The General report of activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme.
This report has been compiled by the EMCDDA in the first half of 2011 as a supporting document for the external evaluation of the 2005–12 EU drugs strategy and its two 2005–08 and 2009–12 action plans.
The Global Drug Survey is an anonymous online survey that addresses how people are using illegal drugs as well as alcohol, tobacco and prescription medications. It combines basic information on what drugs people use, how often they take them, and the medical, social and legal consequences of...
The UNODC Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme enhances the capacity of Member States in priority regions to generate, manage, analyse, report and use synthetic drug information to design effective policy and programme interventions.